Baseline characteristics of the patients based on the specific SF gene mutation
| Parameters . | SRSF2 (n = 136) . | U2AF1 (n = 67) . | SF3B1 (n = 47) . | ZRSR2 (n = 8) . |
|---|---|---|---|---|
| Age ≥ 60 y | 116 (85) | 56 (84) | 38 (81) | 7 (88) |
| M/C mutation | P95H (n = 54) | S34F (n = 36) | K700E (n = 23) | R290Q (n = 2) |
| s/t-AML | 60 (44) | 36 (54) | 28 (60) | 7 (88) |
| CTG | n = 129 | n = 67 | N = 47 | N = 8 |
| AR | 31 (24) | 29 (43) | 22 (47) | 5 (62) |
| Complex | 20 (15) | 13 (19) | 17 (36) | 3 (37) |
| TP53 mutation | 13 (9) | 11 (16) | 12 (25) | 2 (25) |
| ELN 2017 AR | 91 (67) | 47 (70) | 37 (79) | 7 (88) |
| INT therapy | 25 (18) | 14 (21) | 12 (25) | 1 (12) |
| LI therapy | 111 (82) | 53 (79) | 37 (79) | 7 (88) |
| With venetoclax | 74 (67) | 35 (66) | 24 (65) | 5 (71) |
| Parameters . | SRSF2 (n = 136) . | U2AF1 (n = 67) . | SF3B1 (n = 47) . | ZRSR2 (n = 8) . |
|---|---|---|---|---|
| Age ≥ 60 y | 116 (85) | 56 (84) | 38 (81) | 7 (88) |
| M/C mutation | P95H (n = 54) | S34F (n = 36) | K700E (n = 23) | R290Q (n = 2) |
| s/t-AML | 60 (44) | 36 (54) | 28 (60) | 7 (88) |
| CTG | n = 129 | n = 67 | N = 47 | N = 8 |
| AR | 31 (24) | 29 (43) | 22 (47) | 5 (62) |
| Complex | 20 (15) | 13 (19) | 17 (36) | 3 (37) |
| TP53 mutation | 13 (9) | 11 (16) | 12 (25) | 2 (25) |
| ELN 2017 AR | 91 (67) | 47 (70) | 37 (79) | 7 (88) |
| INT therapy | 25 (18) | 14 (21) | 12 (25) | 1 (12) |
| LI therapy | 111 (82) | 53 (79) | 37 (79) | 7 (88) |
| With venetoclax | 74 (67) | 35 (66) | 24 (65) | 5 (71) |
The table does not include 8 patients with >1 SF gene mutation.
M/C; most common; n, number; s/t-AML: secondary or therapy-related AML; CTG, cytogenetics; AR, adverse risk; ELN, European LeukemiaNet; INT, intensive; LI, low intensity.